Apoptosis in hypertensive heart disease

Current Opinion in Cardiology

Volumn 13, Issue 5, 1998, Pages 317-325

  Díez, Javier ^a   Fortuño, María Antonia ^a   Ravassa, Susana ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; INTERLEUKIN 6; PROTEIN BCL 2; PROTEIN P53; SOMATOMEDIN;

APOPTOSIS; DISEASE COURSE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEREDITY; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0031736545     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199809000-00005     Document Type: Review

References (77)

1. Kannel WB, Belanger AJ: Epidemiology of heart failure. Am Heart J 1991, 121:951-957.
2. Levy D, Larson MG, Varsan RS, Kannel WB, Ho KKL: The progression from hypertension to congestive heart failure. JAMA 1996, 275:1557-1562.
3. Anversa P, Olivetti G, Leri A, Liu Y, Kajstura J: Myocyte death and ventricular remodeling. Curr Opin Nephrol Hypertens 1997, 6:169-176.
4. Wagoner LE, Walsh RA: The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol 1996, 11:237-244.
5. Weber KT: Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997, 96:4065-4082. Reviews various lines of evidence that implicate angiotensin II-mediated connective tissue accumulation in the progressive compromise of cardiac function and the development of heart failure.
6. Vaux DL: Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 1993, 90:786-789.
7. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462.
8. Yuan J: Molecular control of life and death. Curr Opin Cell Biol 1995, 7:211-214.
9. Schwartz SM: Cell death and the caspase cascade. Circulation 1998, 97:227-229. Addresses the factors that control the activation of the different members of the caspase cascade.
10. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest 1998, 101:890-898. This article investigated some of the mechanisms through which binding or phagocytosis of apoptotic cells induces active anti-inflammatory or suppressive properties in human macrophages.
11. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119:493-501.
12. Majno G, Joris I: Apoptosis, oncosis, and necrosis: an overview of cell death. J Cell Biol 1995, 267:1449-1455.
13. Bromme HJ, Holtz J: Apoptosis in the heart: when and why? Mol Cell Biochem 1996, 163:261-275.
14. Hamet P, Richard L, Dam TV, Teiger E, Orlov SN, Gaboury L, Gossard F, Tremblay J: Apoptosis in target organs in hypertension. Hypertension 1995, 26:642-648.
15. Li P, Zhang X, Capasso JM, Meggs LG, Sonenblick EH, Anversa P: Myocyte loss and left ventricular failure characterize the long term effects of coronary artery narrowing or renal hypertension in rats. Cardiovasc Res 1993, 27:1066-1075.
16. Diez J, Panizo A, Hernández M, Pardo J: Is the regulation of apoptosis altered in smooth muscle cells of adult spontaneously hypertensive rats? Hypertension 1997, 29:776-780. This article demonstrated that regulation of apoptosis is altered in cardiac cells of spontaneously hypertensive rats and that the local renin-angiotensin system may be involved in such an alteration.
17. Hamet P: Proliferation and apoptosis in hypertension. Curr Opin Nephrol Hypertens 1995, 4:1-7.
18. de Blois D, Tea BS, Dam TV, Tremblay J, Harriet P: Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 1997, 29(part 2):340-349. The authors documented that some antihypertensive drugs modulate apoptosis in vascular cells of spontaneously hypertensive rats independently of blood pressure reduction.
19. Hamet P, Moreau P, Dam TV, Orlov S, Tea BS, de Blois D, Tremblay J: The time window of apoptosis: a new component in the therapeutic strategy for cardiovascular remodeling. J Hypertens 1996, 14(suppl 5):S65-S70.
20. Yeh ETH: Life and death in the cardiovascular system. Circulation 1997, 95:782-786.
21. MacLellan WR, Schneider MD: Death by design: programmed cell death in cardiovascular biology and disease. Circ Res 1997, 81:137-144. The authors review the current status of knowledge regarding apoptosis as it pertains specifically to the cardiovascular system.
22. Pfeffer JM, Pfeffer MA, Fishbein MC, Frohlich DE: Cardiac hypertensive rat. Am J Physiol 1979, 237:H461-H468.
23. Mirsky I, Pfeffer JM, Pfeffer MA, Braunwald E: The contractile state as a major determinant in the evolution of left ventricular dysfunction in the spontaneously hypertensive rat. Circ Res 1983, 53:767-778.
24. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OHL: Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 1995, 91:161-170.
25. Bing OHL, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, Sen S, Conrad HC: The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol 1995, 27:383-396.
26. Díez J, Panizo A, Hernández M, Vega F, Sola I, Fortuño MA, Pardo J: Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension 1997, 30:1029-1034. This article showed that the timing and mechanisms responsible for apoptosis and hypertrophy of cardiomyocytes are different in spontaneously hypertensive rats. Whereas hypertrophy seems to be an earlier alteration that develops in parallel with hypertension, apoptosis develops later in association with overactivity of the local ACE.
27. Li Z, Bing OHL, Long X, Robinson KG, Lakatta EG: Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol 1997, 272:H2313-H2319. This is an interesting report showing that increased numbers of apoptotic cells are present in failing SHR hearts. Administration of the ACE inhibitor captopril, which ameliorates heart failure in this model, is associated with a reduction in the exaggerated apoptosis that accompanies heart failure.
28. Linzbach AJ: Heart failure from the point of view of quantitative anatomy. Am J Cardiol 1960, 5:370-382.
29. Anversa P, Li P, Zhang X, Olivetti G, Caspasso JM: Ischemic myocardial injury and ventricular remodeling. Cardiovasc Res 1993, 27:145-157.
30. Olivetti G, Melissari M, Balbi T, Quaini F, Cigola E, Sonnenblick EH, Anversa P: Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 1994, 28:1199-1208.
31. Trippodo NC, Frohlich ED: Similarities of genetic (spontaneous) hypertension: man and rat. Circ Res 1981, 48:309-319.
32. Narula J, Haider N, Virmani R, Disalvo TG, Kolodgie FD, Hajjar RJ, et al.: Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996, 335:1182-1189.
33. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P: Apoptosis in the failing human heart. N Engl J Med 1997, 336:1131-1141.
34. Liu Y, Cigola E, Cheng W, Kajstura J, Olivetti G, Hintze TH, Anversa P: Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest 1995, 73:771-778.
35. Page DL, Caulfield JB, Kastor JA, De Sanctis RW, Sanders CA: Myocardial changes associated with cardiogenic shock. N Engl J Med 1971, 285:133-137.
36. Caulfield JB, Leinbahc R, Gold H: The relationship of myocardial infarct size and prognosis. Circulation 1976, 53(suppl I):141-144.
37. Reffer JM, Reffer MA, Braunwald E: Influence of chronic captopril therapy on the infarcted left ventricle of rat. Circ Res 1985, 57:84-95.
38. Olivetti G, Caspasso JM, Meggs LG, Sonnenblick EH, Anversa P: Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991, 68:856-869.
39. Takahashi T, Schunkert H, Isoyama S, Wei JY, Nadal-Ginard B, Grossman W, Izumo S: Age-related differences in the expression of proto-oncogene and contractile protein genes in response to pressure overload in rat myocardium. J Clin Invest 1992, 89:939-946.
40. Bing OHL: Hypothesis, apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 1994, 26:943-948.
41. Booz GW, Baker KM: Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 1995, 30:537-543.
42. Anversa P, Kajstura J, Olivetti P: Myocyte death in heart failure. Curr Opin Cardiol 1996, 11:245-251.
43. 1 (I) collagen mRNA accumulation in the endocardium and at sites of degenerating single myocardial cells.
44. Teiger E, Dam TV, Richard L, Wisnewsky C, Tea BS, Gaboury L, et al.: Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996, 97:2891-2897.
45. Cheng W, Li B, Kajstura J, Li P, Wolin MS, Sonnenblick EH, et al.: Stretch-induced programmed myocyte cell death. J Clin Invest 1995, 96:2247-2259.
46. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M: Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 1994, 75:426-433.
47. Long X, Boluy O, Hipolito ML, Lundbergh MS, Zheng JS, O'Neill L, et al.: p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. J Clin Invest 1997, 99:2635-2643. This study showed that exposure of cardiomyocytes to prolonged hypoxia resulted in apoptosis and was accompanied by increased p53 activity and expression.
48. Kozàkovà M, Palombo C, Pratali L, Pittella G, Galetta F, L'Abatte A: Mechanisms of coronary flow reserve impairment in human hypertension: an integrated approach by transthoracic and transesophageal echocardiography. Hypertension 1997, 29:551-559.
49. Susic D, Nunez E, Hosoya K, Frohlich ED: Coronary hemodynamics in aging spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens 1998, 16:231-237.
50. 1 receptor subtype.
51. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997, 29:859-870. This article can be considered complementary to Cigola et al. [50••], because it demonstrated that angiotensin II also induced apoptosis in adult ventricular cardiomyocytes.
52. 1 receptor subtype. Circ Res 1993, 73:413-423.
53. Kijima K, Matsubara H, Murasawa S, Maruyama K, Mori Y, Ohkubo N, et al.: Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res 1996, 79:887-897.
54. 1 blockade with losartan.
55. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM: Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 1995, 92:8031-8035.
56. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, et al.: Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilatation, wall stress, and cardiac hypertrophy. J CNn Invest 1997, 100:1991-1997. An investigation of the ability of insulin-like growth factor 1 to oppose cardiomyocyte apoptosis after experimentally induced myocardial infarction.
57. Parrizas M, Le Roith D: Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the Bcl-xL gene product. Endocrinology 1997, 138:1355-1358.
58. Jung YK, Miura M, Yuan J: Suppression of interleukin-1 beta converting enzyme-mediated cell death by insulin-like growth factor. J Biol Chem 1996, 271:5112-5117.
59. Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Lango RP, Benstein JA, Slater WR, Catanese V: Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation 1994, 89:799-809.
60. Engelman GL, Boehm KD, Haskell JF, Khairallah PA, Ilan J: Insulin-like growth factors and neonatal cardiomyocyte development: ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats. Mol Cell Endocrinol 1989, 63:1-4.
61. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, et al.: Expression clonning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 1995, 92:1142-1146.
62. Sheng Z, Pennica D, Wood WI, Chien KR: Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development (Cam) 1996, 122:419-428.
63. Fujio Y, Kunisada K, Hirota H, Yamauchi-Takihara K, Kishimoto T: Signals through gp130 upregulate Bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J Clin Invest 1997, 99:2898-2905. Elucidates the molecular mechanisms of the protective effects of interleukin 6-related cytokines in cardiomyocytes.
64. Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T: Hypoxie stress induces cardiac myocyte-derived interleukin-6. Circulation 1995, 91:1520-1524.
65. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
66. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Lieberman DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of Bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 1994, 9:1799-1805.
67. Pierzchalski P, Reiss K, Cheng W, Cirielli C, Kajstura J, Nitahara JA, et al.: p53 induces myocyte apoptosis via activation of the renin-angiotensin system. Exp Cell Res 1997, 234:57-65. This study provided the first demonstration that p53 leads to apoptosis of cardiomyocytes via the activation of the cellular renin-angiotensin system.
68. Kim KK, Soonpaa MH, Daud AI, Koh GI, Kim JS, Field LJ: Tumor suppressor gene expression during normal and pathologic myocardial growth. J Biol Chem 1994, 269:22607-22613.
69. McDonnell TJ, Beham A, Sarkiss M, Andersen MM, Lo P: Importance of Bcl-2 family in cell death regulation. Experientia 1996, 52:1008-1017.
70. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997, 3:614-620. Concise overview of the role of Bcl-2 gene products in the regulation of apoptosis.
71. Oltvai ZN, Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 1994, 79:189-192.
72. Kirshenbaum LA, de Moissac D: The Bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation 1997, 96:1580-1585. This interesting report provided the first indication for the operation of Bcl-2 gene in ventricular myocytes as an antiapoptotic factor.
73. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of Gi cyclin-dependent kinases. Cell 1993, 75:805-816.
74. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704.
75. MacLeod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995, 9:935-944.
76. Canman CE, Gilmer TM, Coutts SB, Kastan MB: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 1995, 9:600-611.
77. Katayose D, Wersto R, Cowan KH, Seth P: Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth Differ 1995, 6:1207-1212.